Nirali N. Shah
Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.
Leads paediatric CAR-T trials at NCI including the first CD22-directed CAR-T, addressing CD19-negative relapse after tisagenlecleucel and blinatumomab.
| Title | Journal | Year |
|---|---|---|
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy | Nature Medicine | 2018 |
Pages like this
not linked directly; found by shared links- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialFELIX
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonRenier J. Brentjens
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonBrigitte C. Widemann
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- TrialINO-VATE ALL
Shares CD22, Acute lymphoblastic leukaemia.
- PersonLouis M. Staudt
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonJames L. Gulley
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonRaffit Hassan
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).